Saturday 17 October 2026
Export CLGN’s income statement to Excel — free account
CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
3.60
0.08
−2.17%
Follow CLGN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 5 | 2 | 7 | 6 | 2 | 4 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 74.36 | 0.00 | 0.00 | 0.00 | 8.86 | 8.86 |
Altman Z-Score |
(16.87) | (6.12) | 4.04 | 6.17 | 15.34 | (3.32) | (8.15) | (6.01) | — | — |
P/S ratio |
7.21 | 80.07 | 6.29 | 317.34 | 10.43 | 12.09 | 12.26 | 3.67 | 54.76 | 54.76 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 172.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(41.05) | (19.67) | (0.82) | 0.35 | 8.53 | (23.31) | (23.55) | (18.74) | (20.65) | (47.33) |
Beneish M-Score |
(3.20) | — | 27.27 | — | (2.16) | (1.74) | 2.18 | 3.06 | 0.22 | — |
P/Operating CF |
(5.82) | (11.90) | (29.38) | (28.36) | (67.39) | (46.45) | (17.34) | 5.75 | (5.03) | (5.03) |
P/B ratio |
2.81 | 3.06 | 2.43 | 2.94 | 3.61 | 16.57 | 6.95 | 3.40 | 9.90 | 9.90 |
Price to Tangible BV |
2.84 | 3.09 | 2.45 | 2.96 | 3.63 | 16.88 | 6.95 | 3.63 | 9.90 | 9.90 |
EV/Sales |
7.00 | 67.05 | 4.33 | 236.33 | 8.01 | 12.43 | 12.98 | 2.58 | 51.64 | 51.64 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 149.45 | 0.00 | 0.00 | 0.00 | 51.64 | 51.64 |
EV/Operating CF |
(1.76) | (2.45) | (17.17) | (5.16) | 50.07 | (17.14) | (5.28) | (10.64) | 0.00 | 0.00 |
EV/FCF |
(1.75) | (2.36) | (12.85) | (4.71) | 132.52 | (15.61) | (4.20) | (6.32) | 0.00 | 0.00 |
Quick Ratio |
2.31 | 4.29 | 8.40 | 9.74 | 14.60 | 1.30 | 1.20 | 2.70 | 3.69 | 1.11 |
Current Ratio |
2.53 | 4.44 | 8.62 | 10.20 | 14.96 | 1.68 | 1.46 | 3.21 | 4.56 | 1.19 |
Net Debt/EBITDA |
0.56 | 0.75 | 4.20 | 1.85 | (51.68) | 0.68 | 0.53 | 1.40 | 0.26 | 0.13 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.22% | 0.50% | 45.28% | 1.98% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 1.40 | 0.06 |
Asset Turnover |
0.16 | 0.02 | 0.30 | 0.01 | 0.50 | 0.57 | 0.24 | 0.60 | 0.08 | 0.01 |
Operating CF/Net income |
0.82 | 0.85 | 0.39 | 0.81 | 10.55 | 0.77 | 0.51 | 0.19 | 0.86 | 0.69 |
Capex/Depreciation |
(0.03) | (0.46) | (0.80) | (1.22) | (2.01) | (0.79) | (2.71) | (2.43) | (0.43) | (0.57) |
Interest Coverage |
— | — | — | (53.26) | 0.30 | (164.68) | (2.31) | (1.95) | (54.42) | (62.44) |
| (117.56%) | (79.46%) | (23.16%) | (43.73%) | 0.96% | (134.83%) | (234.83%) | (155.43%) | (294.98%) | (387.61%) | |
| (77.90%) | (62.87%) | (19.53%) | (38.04%) | 0.76% | (53.48%) | (114.48%) | (74.21%) | (98.89%) | (129.91%) | |
ROIC |
(5,478.53%) | (824.30%) | (329.47%) | (410.20%) | 2.25% | (309.13%) | (1,543.49%) | 0.00% | (326.75%) | (1,044.57%) |
Return on Tangible Assets |
(207.46%) | (132.87%) | (25.47%) | (53.70%) | 0.53% | (131.41%) | (285.38%) | (98.47%) | (99.06%) | (529.40%) |
Average Days of Receivables |
34.48 | 413.19 | 13.09 | 673.85 | 16.20 | 63.58 | 54.95 | 37.56 | 77.40 | 4,714.22 |
Research and Development Expense of Revenue |
345.30% | 2,041.75% | 95.67% | 3,429.77% | 48.79% | 66.24% | 190.42% | 77.32% | 843.66% | 5,731.33% |
Selling, General and Administrative Expense of Revenue |
203.80% | 1,092.43% | 54.71% | 2,254.52% | 37.98% | 76.08% | 157.72% | 74.25% | 497.71% | 3,772.29% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.04 | 0.05 | 0.10 |
Share Based Compensation of Revenue |
42.13% | 333.79% | 17.67% | 727.09% | 10.21% | 27.28% | 48.53% | 28.60% | 297.92% | 1,219.28% |
Graham Net Nets |
0.12 | 0.19 | 0.32 | 0.28 | 0.24 | (0.01) | (0.06) | 0.21 | 0.04 | 0.04 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 47.33 | 0.00 | 0.00 | 0.00 | 45.32 | 0.00 |
Earnings Yield |
(67.02%) | (40.56%) | (10.25%) | (17.91%) | 1.34% | (7.80%) | (39.81%) | (21.37%) | 11.28% | 11.28% |
Free Cash Flow Yield |
(55.54%) | (35.45%) | (5.36%) | (15.82%) | 0.58% | (6.59%) | (25.21%) | (11.13%) | 0.00% | 0.00% |
Revenue per Share |
1.94 | 0.45 | 9.62 | 0.27 | 15.69 | 8.91 | 4.65 | 11.43 | 1.81 | 0.41 |
Operating CF per Share |
(7.72) | (12.30) | (2.43) | (12.42) | 2.51 | (6.46) | (11.44) | (2.78) | (19.36) | (27.26) |
Capex per Share |
(0.02) | (0.42) | (0.78) | (1.19) | (1.56) | (0.75) | (2.93) | (1.90) | (0.48) | (0.69) |
Free Cash Flow per Share |
(7.74) | (12.72) | (3.20) | (13.61) | 0.95 | (7.22) | (14.37) | (4.67) | (19.85) | (27.95) |
Cash per Share |
4.88 | 10.61 | 23.63 | 26.90 | 43.45 | 4.86 | 7.63 | 12.56 | 19.29 | 5.35 |
Shareholders Equity per Share |
4.98 | 11.76 | 24.88 | 29.26 | 45.26 | 6.50 | 8.20 | 12.36 | 9.84 | 7.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.98 | 11.76 | 24.88 | 29.26 | 45.26 | 6.50 | 8.20 | 12.36 | 9.84 | 7.26 |
Free Cash Flow |
(9.45) | (14.57) | (3.65) | (15.01) | 0.95 | (4.97) | (7.16) | (2.05) | (5.29) | (5.63) |
Working Capital |
4.08 | 10.21 | 24.77 | 28.55 | 42.07 | 2.29 | 1.58 | 4.94 | 5.05 | 0.36 |
Capital Expenditures |
(0.03) | (0.48) | (0.89) | (1.32) | (1.56) | (0.52) | (1.46) | (0.83) | (0.13) | (0.14) |
Net Current Asset Value |
2.04 | 7.94 | 22.24 | 26.17 | 38.98 | (0.69) | (1.62) | 3.84 | 1.00 | (0.34) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 1,926.71 | 0.00 | 0.00 | 0.00 | 51.64 | 51.64 |
Capex to Sales |
0.01 | 0.94 | 0.08 | 4.40 | 0.10 | 0.08 | 0.63 | 0.17 | 0.27 | 1.67 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 2,509.12 | 0.00 | 0.00 | 0.00 | 54.76 | 54.76 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 0.45 | 0.40 | 0.36 | 0.28 | 0.31 | 0.23 | 0.24 | 0.29 | 0.22 |
Cash ROIC |
(78.51%) | (56.88%) | (6.60%) | (24.23%) | 1.07% | (63.54%) | (90.51%) | (18.67%) | (46.28%) | (214.81%) |
Accounts Receivable Turnover |
5.88 | 1.06 | 23.19 | 0.48 | 17.74 | 8.66 | 5.36 | 16.23 | 0.82 | 0.10 |
Accounts Payable Turnover |
1.13 | 1.76 | 1.88 | 0.37 | 2.19 | 3.68 | 2.58 | 2.26 | 0.01 | 0.00 |
Inventory Turnover |
1.65 | 2.82 | 1.86 | 0.32 | 1.71 | 2.79 | 2.21 | 3.27 | 0.09 | 0.00 |
Average Days of Payables |
266.65 | 195.42 | 179.66 | 1,033.86 | 188.23 | 97.03 | 161.81 | 136.85 | 20,513.00 | 0.00 |
Days of Inventory on Hand |
250.47 | 98.83 | 130.89 | 1,304.88 | 196.79 | 153.44 | 172.50 | 179.09 | 4,915.33 | 0.00 |
Average Receivables |
0.40 | 0.49 | 0.47 | 0.62 | 0.88 | 0.71 | 0.43 | 0.31 | 0.59 | 0.85 |
Average Payables |
0.74 | 0.93 | 1.06 | 1.08 | 0.92 | 0.82 | 0.73 | 0.73 | 1.16 | 1.16 |
Average Inventory |
0.51 | 0.58 | 1.07 | 1.26 | 1.17 | 1.08 | 0.85 | 0.51 | 0.17 | 0.17 |
Average Assets |
14.75 | 26.42 | 35.95 | 44.50 | 31.03 | 10.80 | 9.75 | 8.42 | 6.09 | 6.08 |
Average Common Equity |
9.77 | 20.90 | 30.31 | 38.70 | 24.80 | 4.28 | 4.75 | 4.02 | 2.04 | 2.04 |
Columns are period end dates · fundamentals updated 6 Oct 2026